Tag: NANS 2024
Nalu Medical presents long-term, holistic outcomes with PNS system at NANS...
Nalu Medical presented interim data from the “landmark” COMFORT randomised controlled trial (RCT)—indicating long-term and holistic pain management outcomes with its peripheral nerve stimulation...
Medtronic announces trial data on closed-loop and DTM SCS therapies at...
At this year’s North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA), Medtronic announced new data from two clinical trials demonstrating...
Boston Scientific announces positive WaveWriter SCS findings from SOLIS trial
Boston Scientific Corporation has announced positive one-year results from the SOLIS randomised controlled trial, demonstrating sustained pain relief using its WaveWriter Alpha spinal cord...
Nevro to highlight 25 scientific abstracts on spinal cord stimulation at...
Nevro Corporation has announced a series of data presentations supporting the use of the company's high-frequency (HFX) 10kHz spinal cord stimulation (SCS) therapy for...
Saluda announces plans to present new EVOKE study data at NANS...
Saluda Medical has announced that its data will be presented at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas,...
SPR Therapeutics announces multiple first-time data presentations set for NANS 2024
SPR Therapeutics has announced that it is set to be featured prominently at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las...
Boston Scientific to present late-breaking data at NANS 2024
Boston Scientific Corporation has announced its clinical data that will be featured at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January,...
Neuralace announces US FDA clearance for Axon therapy ahead of NANS...
Neuralace Medical has announced the US Food and Drug Administration (FDA) clearance of its “groundbreaking” Axon therapy for the treatment of chronic painful diabetic...
